SABS Stock Price Chart
SABS Earnings
SAB Biotherapeutics Inc
$0
0%
$0
At close: Jun 18, 16:00:00 GMT-4
$0
0%
$0
Post-market: Jun 18, 20:00:00 GMT-4
Back
SAB Biotherapeutics Inc (SABS) Earnings
Latest Earnings Results: Q1 '26
Reported: 2026-05-12
Historical Earnings
Quarterly
Annual
EPS
Revenue
Earnings FAQ
How did SABS's recent EPS compare to expectations?
How did SAB Biotherapeutics Inc SABS's revenue perform in the last quarter?
What is the revenue estimate for SAB Biotherapeutics Inc?
What's the earning quality score for SAB Biotherapeutics Inc?
When does SAB Biotherapeutics Inc report earnings?
What are SAB Biotherapeutics Inc's expected earnings?
Did SAB Biotherapeutics Inc beat earnings expectations?
Key Stats
Prev.Close
--
Open
--
Day's Range
-
52 week range
-
Volume
--
Avg.Volume
--
Dividend yield
--
EPS (TTM)
--
Market Cap
--
What is SABS?
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The company is headquartered in Miami Beach, Florida and currently employs 86 full-time employees. The company went IPO on 2021-01-12. The firm is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
